
Prelude Therapeutics Incorporated PRLD
$ 3.31
-0.3%
Country |
|
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
77 M |
Market Cap[1] |
$ 255 M |
EBITDA (LTM) |
$ -60.1 M |
P/E (LTM) |
-5.79661 |
P/S (LTM) |
12.201112 |
EPS (LTM) |
-0.59 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
ММЦБ
GEMA
|
- | - | - | MOEX | ||
|
Lyra Therapeutics
LYRA
|
- | - | $ 24.9 M | Nasdaq Global Market | ||
|
ОЗОН Фармацевтика
OZPH
|
- | - | - | MOEX | ||
|
Промомед
PRMD
|
- | - | - | MOEX | ||
|
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
ESSA Pharma
EPIX
|
- | - | $ 8.86 M | Nasdaq Capital Market | ||
|
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | ||
|
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | ||
|
Merus N.V.
MRUS
|
- | - | $ 5.78 B | Nasdaq Global Select Market | ||
|
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | Nasdaq Global Select Market | ||
|
Annexon
ANNX
|
$ 3.62 | 4.18 % | $ 561 M | Nasdaq Global Select Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
Galapagos NV
GLPG
|
- | - | $ 1.83 B | Nasdaq Global Select Market | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
- | -4.36 % | $ 27 M | Nasdaq Capital Market | ||
|
Idera Pharmaceuticals
IDRA
|
- | -23.04 % | $ 26.6 M | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Verona Pharma plc
VRNA
|
- | - | $ 69.7 B | Nasdaq Global Select Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
$ 4.63 | 21.05 % | $ 20 M | Nasdaq Capital Market | ||
|
Achieve Life Sciences
ACHV
|
$ 6.78 | 0.89 % | $ 296 M | Nasdaq Capital Market | ||
|
Leap Therapeutics
LPTX
|
- | 368.57 % | $ 41.9 M | Nasdaq Global Market | ||
|
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | ||
|
Guardion Health Sciences
GHSI
|
- | -0.31 % | $ 3.64 M | Nasdaq Capital Market | ||
|
Opiant Pharmaceuticals
OPNT
|
- | - | $ 109 M | Nasdaq Global Select Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
ImmunoGen
IMGN
|
- | - | $ 7.92 B | Nasdaq Global Select Market | ||
|
Vascular Biogenics Ltd.
VBLT
|
- | -8.77 % | $ 12.4 M | Nasdaq Global Select Market | ||
|
Bristol-Myers Squibb Company
BMY
|
$ 59.5 | -3.02 % | $ 121 B | NYSE,SPB | ||
|
Cidara Therapeutics
CDTX
|
- | - | $ 1.41 B | Nasdaq Global Market | ||
|
BioLineRx Ltd.
BLRX
|
$ 1.1 | -1.79 % | $ 2.71 B | Nasdaq Capital Market | ||
|
Iterum Therapeutics
ITRM
|
- | - | $ 591 K | Nasdaq Global Select Market | ||
|
Virpax Pharmaceuticals
VRPX
|
- | -45.12 % | $ 2.85 M | Nasdaq Global Select Market | ||
|
Navidea Biopharmaceuticals
NAVB
|
- | -2.99 % | $ 2.47 M | NYSE American | ||
|
Stealth BioTherapeutics Corp
MITO
|
- | - | $ 23.9 M | Nasdaq Global Select Market | ||
|
OncoSec Medical Incorporated
ONCS
|
- | 31.87 % | $ 1.61 M | Nasdaq Global Select Market | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | ||
|
Landos Biopharma
LABP
|
- | 0.58 % | $ 144 M | Nasdaq Global Market | ||
|
CASI Pharmaceuticals
CASI
|
- | - | $ 35.4 M | Nasdaq Capital Market | ||
|
ContraFect Corporation
CFRX
|
- | -5.16 % | $ 5.39 M | Nasdaq Capital Market | ||
|
Sigilon Therapeutics
SGTX
|
- | - | $ 728 M | Nasdaq Global Select Market | ||
|
NGM Biopharmaceuticals
NGM
|
- | - | $ 127 M | Nasdaq Global Select Market,SPB | ||
|
Regulus Therapeutics
RGLS
|
- | - | $ 155 M | Nasdaq Global Select Market | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.